135,800 Shares in Pfizer Inc. $PFE Acquired by WINTON GROUP Ltd

Key Points

• WINTON GROUP Ltd acquired 135,800 Pfizer shares worth approximately $3.27 million in the second quarter. Institutional investors collectively own 68.36% of Pfizer.
• Analysts maintain a generally cautious outlook, with a consensus “Hold” rating and an average price target of $28.39; Pfizer shares recently opened at $27.69.
• Pfizer exceeded quarterly earnings and revenue expectations, reporting $0.77 EPS and $15.03 billion in revenue. The company also declared a quarterly dividend of $0.43 per share, equivalent to a 6.2% annualized yield.

WINTON GROUP Ltd purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 135,800 shares of the biopharmaceutical company's stock, valued at approximately $3,270,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. Godfrey Financial Associates Inc. bought a new stake in Pfizer in the fourth quarter valued at approximately $26,000. Keb Asset Management LLC bought a new position in Pfizer during the second quarter worth $26,000. Field & Main Bank acquired a new position in Pfizer in the second quarter valued at $27,000. HFM Investment Advisors LLC grew its holdings in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. raised its position in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 566 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Guggenheim cut their target price on Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. HSBC boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a "hold" rating in a research note on Thursday. Cantor Fitzgerald restated a "neutral" rating and set a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. UBS Group reiterated a "neutral" rating and issued a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Finally, BMO Capital Markets dropped their target price on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $28.39.

Pfizer Price Performance

Shares of NYSE:PFE opened at $27.69 on Friday. The stock's 50 day moving average is $26.35 and its 200-day moving average is $26.37. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $29.21. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a market capitalization of $157.82 billion, a price-to-earnings ratio of 36.43, a PEG ratio of 1.86 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the previous year, the business posted $0.78 EPS. Pfizer's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer's payout ratio is 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer's products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.